BRTX BioRestorative Therapies, Inc.
Healthcare$0.25+20.10%ClosedMarket Cap: $2.2M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.62
P/S
5.23
EV/EBITDA
0.09
DCF Value
$-4.89
FCF Yield
-636.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
92.1%
Operating Margin
-3975.0%
Net Margin
-3089.6%
ROE
-423.8%
ROA
-238.3%
ROIC
-470.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $23.2K | 68.1% | $-3.4M | $-2.2M | $— | — |
| Q4 null | $19.6K | 91.7% | $-3.8M | $-3.2M | $— | — |
| FY null | $359.7K | 93.4% | $-15.6M | $-14.2M | $— | — |
| Q3 null | $11.8K | 10.4% | $-3.7M | $-3.0M | $— | — |
| Q2 null | $303.3K | 97.1% | $-3.3M | $-2.7M | $— | — |
| Q1 null | $25.0K | 88.4% | $-4.8M | $-5.3M | $— | — |
| Q4 null | $43.3K | 92.3% | $-2.7M | $-1.6M | $— | — |
| FY null | $401.0K | 93.0% | $-11.6M | $-9.0M | $— | — |
| Q3 null | $233.6K | 92.2% | $-2.3M | $-1.1M | $— | — |
| Q2 null | $89.1K | 92.7% | $-2.5M | $-4.0M | $— | — |
| Q1 null | $35.0K | 100.0% | $-4.1M | $-2.2M | $— | — |
| Q4 2023 | $19.3K | -121.3% | $-3.2M | $1.2M | $0.25 | — |